Ticagrelor Monotherapy After One Month Algorithm Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Complete the patient factors below. This decision aid supports, but does not replace, individualized clinical judgment.

Enter the number of elapsed days after the index percutaneous coronary intervention. The one-month landmark is approximate; confirm the actual calendar date.

The one-month ticagrelor-monotherapy recommendation assessed here is specifically based on ACS-after-PCI guidance.

Use a validated assessment, such as ARC-HBR, together with clinical context.

Consider prior stent thrombosis, complex PCI, multivessel disease, and other relevant factors.

For example, atrial fibrillation with an indication for long-term anticoagulation.

Consider adherence, bleeding, dyspnea, contraindications, and other intolerance.

A positive response needs clinical assessment rather than automatic de-escalation.

Clinical context

Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor remains the default strategy for at least 12 months after ACS in patients who are not at high bleeding risk. The 2025 ACC/AHA ACS guideline recommends transition to ticagrelor monotherapy at or beyond one month after PCI for patients who have tolerated ticagrelor-based DAPT, as a bleeding-reduction strategy.

How to use this pathway

  • Confirm the index presentation, PCI date, current drugs, adherence, contraindications, and clinical stability.
  • Use a validated bleeding-risk framework and review ischemic and procedural risk rather than relying on a single yes/no item.
  • Patients requiring long-term oral anticoagulation need a separate antithrombotic strategy; the ACS guideline generally favors a P2Y12 inhibitor, preferably clopidogrel, after early aspirin discontinuation.
  • This simplified tool does not calculate a validated risk score and cannot replace review of the full guideline, angiographic findings, or specialist judgment.

References

Rao SV, O'Donoghue ML, Ruel M, et al.

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025.

doi:10.1016/j.jacc.2024.11.009
Ge Z, Kan J, Gao X, et al.; ULTIMATE-DAPT investigators.

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after PCI in patients with ACS (ULTIMATE-DAPT). Lancet. 2024;403:1866–1878.

doi:10.1016/S0140-6736(24)00473-2 · PMID: 38599220
Kim BK, Hong SJ, Cho YH, et al.

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With ACS: The TICO Randomized Clinical Trial. JAMA. 2020;323:2407–2416.

doi:10.1001/jama.2020.7580
Clinical disclaimer: This tool is an educational decision aid, not a validated clinical prediction rule or a substitute for professional judgment. Do not use it as the sole basis for changing antiplatelet therapy. Active bleeding, recurrent ischemia, suspected stent thrombosis, or clinical instability requires urgent patient-specific assessment. Confirm current local guidance, drug labeling, contraindications, and the patient's treatment plan.